impacting

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

MORNINGBASEBALL AND GAME ON MEDIA SOLUTIONS FORGE PARTNERSHIP TO REVOLUTIONIZE THE BASEBALL STREETWEAR INDUSTRY

November 6th, 2023. Los Angeles, CA– MorningBaseball, a start-up baseball apparel company, has partnered with Game On Media Solutions (GOMS), an innovative media, content and sponsorship representation company, with the goal of transforming the baseball streetwear industry. MorningBaseball aims to inspire and motivate baseball players worldwide to achieve their dreams and conquer the challenges they face on their journey to the next level. One of the brand’s goals is to highlight and support athletes in prioritizing their mental and physical well-being and finding a healthy balance between their passion for